While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

At CTS Nordics, Arnaud Dourlens explained how Sanofi has engaged between clinical operations and supply teams earlier to ...

The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...

Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...

Dash Solutions has introduced dashClinical, a payment solution that provides real-time, secure payments to clinical trial ...

The data was announced during the 2025 North American Menopause Society (NAMS) Annual Meeting. Image credit: shisu_ka / Shutterstock.com. Entera Bio’s osteoporosis candidate for postmenopausal women ...

Inhibrx’s DR5-targeting antibody has more than doubled PFS compared with placebo in a Phase II trial in chondrosarcoma, a rare bone cancer with no approved targeted therapies. Image credit: Kateryna ...

Electra is assessing ELA026 for haematologic cancers, following promising initial clinical data. Credit: Motortion Films / Shutterstock.com. Electra Therapeutics has raised $183m in an oversubscribed ...

Neuphoria Therapeutics’ lead candidate, BNC210, has failed to show efficacy in the Phase III AFFIRM-1 trial in social anxiety disorder. Image credit: Blueastro via Shutterstock.com. Neuphoria ...

Johnson & Johnson’s targeted therapeutic combination, Tecvayli-Darzalex Faspro, performed better than investigator’s choice standard of care in a Phase III trial recruiting patients with R/R multiple ...

The vaccine was generally well tolerated among the paediatric population, with no unexpected safety signals reported. Credit: PeopleImages/Shutterstock.com. Bavarian ...